Dr. Daphne Brooks Stewart, MD

Dr. Stewart practices at Urology - Nch Urology - HOPD in Los Angeles, California.

Dr. Stewart's NPI, 1598879918, was assigned on August 19, 2006. Dr. Stewart graduated from Vagelos College of Physicians and Surgeons in 1998. Dr. Stewart holds California license A69829.

Dr. Stewart's primary practice is Urology - Nch Urology - HOPD, at 1516 San Pablo St, Los Angeles, CA 90033.

Dr. Stewart's primary practice is Urology - Nch Urology - HOPD in Los Angeles, California. Dr. Stewart is also affiliated with Los Angeles General Medical Center. The medical group on file is USC Care Medical Group. Dmand AI also links Dr. Stewart to 2 more hospitals, 2 hospital outpatient departments, 2 other sites and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Stewart practices, 8 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Stewart's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Stewart is board certified in hematology by the American Board of Internal Medicine. Dr. Stewart is licensed in California.

Dmand AI lists breast cancer, chronic leukemia, lung cancer and lymphoma among the conditions Dr. Stewart treats.

CMS data shows 297 Medicare services from Dr. Stewart across 7 procedure codes in 2024, for 142 Medicare patients. Medicare paid $24,353 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 142 Medicare patients who saw Dr. Stewart in 2024. The largest group is 65 to 74, with 72 patients. 75% of them have cancer, and 75% have high blood pressure. 41% are also on Medicaid. Their average risk score is 2.40, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Stewart's median patient age at 52, with 70% women.

In 2024, Dr. Stewart wrote 234 Medicare Part D claims for 59 patients. 94% of them were for generic drugs. CMS names the drug for 129 of them, across 5 drugs with 11 or more claims each, at $3,846 in total drug cost. In 2023, CMS named 154 claims across 5 drugs.

Dr. Stewart accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Stewart as offering telehealth.

Dmand AI links 6 papers to Dr. Stewart, published from 2014 to 2025. 2020 was the busiest year, with 2. Dr. Stewart's most frequent co-authors are Joanne E. Mortimer, MD, Laura Kruper, MD and Yuan Yuan, MD, PhD.

Dmand AI links Dr. Stewart to 5 clinical trials, 2 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Breast Neoplasms, Carcinosarcoma and Endometrial Neoplasms.

CMS Open Payments shows 38 general payments to Dr. Stewart from 18 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 55% of the total. Seagen Inc. paid the most, $1,025.

Dr. Stewart graduated from Vagelos College of Physicians and Surgeons in 1998. Dr. Stewart is a member of ASCO.

Dr. Stewart is in network with 9 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.